Targeting uncontrolled inflammation may hold the key to treating therapy-resistant cancers


More information: Shelby E. Compton et al, LKB1 controls inflammatory potential through CRTC2-dependent histone acetylation, Molecular Cell (2023). DOI: 10.1016/j.molcel.2023.04.017 https://healthmedicinet.com/i/targeting-uncontrolled-inflammation-may-hold-the-key-to-treating-therapy-resistant-cancers/